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Abstract
Background: Genes do not act in isolation but instead as part of complex regulatory networks. To understand
how breast tumors adapt to the presence of the drug letrozole, at the molecular level, it is necessary to consider
how the expression levels of genes in these networks change relative to one another.
Methods: Using transcriptomic data generated from sequential tumor biopsy samples, taken at diagnosis,
following 10-14 days and following 90 days of letrozole treatment, and a pairwise partial correlation statistic, we
build temporal gene coexpression networks. We characterize the structure of each network and identify genes that
hold prominent positions for maintaining network integrity and controlling information-flow.
Results: Letrozole treatment leads to extensive rewiring of the breast tumor coexpression network. Approximately
20% of gene-gene relationships are conserved over time in the presence of letrozole while 80% of relationships are
condition dependent. The positions of influence within the networks are transiently held with few genes stably
maintaining high centrality scores across the three time points.
Conclusions: Genes integral for maintaining network integrity and controlling information flow are dynamically
changing as the breast tumor coexpression network adapts to perturbation by the drug letrozole.
Background
Gene signatures are routinely used to predict drug action,
patient relapse, overall survival, and treatment response to
stratify breast cancer patients for tailored therapies [1].
Gene signatures are derived from genome-wide expression
profiles that capture the global state of gene transcription
at a given moment in time. The utility of these genome-
wide measures largely depends on the computational
methods used to transform the data into an interpretable
form. Conventional analysis methods detect patterns of
genes whose differential expression can distinguish
between various biological conditions, for example, drug
treated and untreated samples. Notably, prognostic or pre-
dictive gene signatures with comparable accuracies tend to
have few, if any, genes in common [2]. However, gene
expression levels are highly correlated and these signatures
do often recapitulate the same signaling pathways reflect-
ing that genes are not acting in isolation but as compo-
nents of larger gene regulatory networks.
It is well established that biological function arises from
context-dependent interactions among the component
parts of the cell [3]. The snapshots of global gene expres-
sion provided by microarray data are a source from which
these context-dependent interactions can be identified.
Genes that are being coregulated will have correlated
expression values and a tendency to function as part of
the same or related regulatory processes [4]. By focusing
on these coexpression relationships in breast cancer we
can maximize the amount of information gained from
genomic data.
An estimated two-thirds of breast cancers are estrogen
receptor positive (ER+) enabling them to respond to
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mitogenic estrogen signaling. Estrogen regulates cell
growth and differentiation influencing the development
and progression of breast cancer by binding to and acti-
vating ERs. ERs regulate gene expression through the
activation or repression of gene transcription and parti-
cipate in cell signaling processes [5]. Anti-estrogen
therapies that block the synthesis of estrogen, such as
letrozole, are routinely used to treat breast cancers.
Letrozole is a third-generation non-steroidal aromatase
inhibitor. Through competitive, reversible binding to the
aromatase enzyme letrozole blocks the production of
estrogen by inhibiting the conversion of androgens into
estrogens. While it is possible to reduce the volume of ER
+ tumors by inhibiting the production of estrogen it is
important to consider that estrogen plays an integral role
in the normal physiology of women by controlling diverse
processes such as cholesterol production and maintenance
of bone density [6]. This suggests that the inhibition of
estrogen will lead to global gene expression changes in the
affected tissues including, but not limited to, those that
block tumor growth.
A study carried out by the Breast Research Group at the
University of Edinburgh has produced gene expression
profiles of ER+ tumors from postmenopausal women in
the course of neoadjuvant treatment with the aromatase
inhibitor letrozole [7]. RNA was isolated from sequential
tumor biopsies taken before treatment and after 10-14
days and 90 days of treatment and used for microarray
analysis. Sets of differentially expressed genes, based on
frequency, magnitude, and significance, were collated with
respect to time. When classified by the Gene Ontology
(GO) database it was shown that these gene sets contain
representatives of diverse biological pathways.
In prior work, Miller et al. found that markers of estro-
gen sensitivity were largely downregulated by letrozole
regardless of whether a tumor responded to the drug [8].
Notably, no single gene was able to consistently discrimi-
nate between clinically responsive and resistant tumor
samples [9]. In addition, a significant reduction in markers
of proliferation by letrozole did not correlate with clinical
response [10]. These findings are consistent with the larger
BIG 1-98 trial which concluded that letrozole induced
changes in ER, progesterone receptor (PGR) and Ki-67
expression levels do not correlate with clinical response
[11]. Taken together these data illustrate the complexity of
estrogen responsive gene regulatory networks and suggest
that there is a letrozole induced gene signature regardless
of response status.
By focusing on gene coexpression relationships as a
complement to differential expression we are able to reveal
a global picture of how the network of affected genes
responds to letrozole perturbation. In this study we deter-
mine how the expression of genes change relative to one
another in response to the aromatase inhibitor letrozole.
We look at how the gene coexpression networks from ER+
breast tumor samples are rewired in response to letrozole
treatment over time. And we determine how this rewiring
changes the set of genes impacting information flow
across the coexpression networks.
Methods
Data description
Publicly available gene expression data were used for dif-
ferential expression and coexpression analyses. The tran-
scriptomic data were generated from sequential biopsies
of ER+ breast tumors from postmenopausal women during
neoadjuvant treatment with letrozole [7,8]. Core biopsy
samples were collected at diagnosis and following 10-
14 days and 90 days of treatment with 2.5 mg/day of letro-
zole. A total of 176 samples were available including 58
samples collected at diagnosis (pre-treatment), 58 samples
collected on treatment day 14 (mid-treatment), and 60
samples collected on treatment day 90 (post-treatment).
RNA was extracted from biopsies containing at least 20%
malignant tissue then amplified and hybridized to Affyme-
trix HG-U133A GeneChip arrays. These data capture tem-
poral gene expression profiles as they change in response
to the presence of letrozole within a natural physiological
context.
Data processing
We downloaded the raw CEL files from the Gene
Expression Omnibus website (GEO GSE20181). We use
a custom CDF from Dai et al. to get the most recent
probe annotations and to ensure a a unique mapping
between probes and genes [12]. The R implementation
of RMA is used to background correct, normalize, and
summarize probe set data [13]. We filter the processed
data to remove Affymetrix spike-in controls.
Differential expression analysis
To identify a set of genes that are differentially expressed
by the drug letrozole, we compare the processed expres-
sion levels of each gene between the pre-treatment sam-
ples and the post-treatment (90 days on drug) samples by
linear modeling. This method was chosen based on it’s
performance across a variety of sample sizes and noise
levels [14]. We set an FDR threshold of 5% to correct for
multiple hypothesis testing. These analyses are performed
in R with the Limma package [13,15].
To identify GO biological processes that are overre-
presented in the up-regulated and down-regulated gene
lists we use the Database for Annotation, Visualization
and Integrated Discovery (DAVID) [16]. Reported p-
values reflect the EASE score (a modified Fisher Exact
p-value) provided by DAVID.
Penrod and Moore BMC Medical Genomics 2013, 6(Suppl 2):S2
http://www.biomedcentral.com/1755-8794/6/S2/S2
Page 2 of 10
Coexpression by partial correlation
To identify direct gene-gene coexpression relationships
among the set of differentially expressed genes over the
course of letrozole treatment we calculate pairwise 1st-
order Spearman partial correlation coefficients using the
expression levels of these genes across patient samples
at each of the three time points separately [17]. This
allows us to generate an independent set of coexpres-
sion relationships for pre-treatment, mid-treatment, and
post-treatment samples. To balance Type I and Type II
error we set a significance threshold of a = 0.01 based
on simulations carried out by de la Fuente et al. [17].
To validate this threshold we use permutation testing.
Permutation tests are designed to randomize the expres-
sion values for each gene, across samples, within each
time point. Following randomization we calculate all
pairwise 1st-order Spearman partial correlation coeffi-
cients and count the number that meet our significance
threshold. This process is repeated 1000 times to gener-
ate a null distribution. The observed number of signifi-
cant pairwise partial correlation relationships, for each
time point, fall outside the upper bound of the matched
null distribution.
Coexpression networks
We build three coexpression networks, one for each time
point, where each node represents one of the differentially
expressed genes and each undirected link indicates a signif-
icant direct correlation between the expression levels of the
pair of genes it connects. We define hubs as nodes that are
statistical outliers by degree and bottlenecks as nodes that
are statistical outliers by betweenness centrality (Figure 2).
We subcategorize nodes into hub bottlenecks, or nodes
that are statistical outliers in both degree and betweenness
centralities, hub nonbottlenecks, or nodes that are outliers
in degree but not betweeness centrality and nonhub bottle-
necks, or nodes that are statistical outliers by betweenness
centrality but not degree. All statistical analyses are per-
formed in R and network characterization is performed
with the igraph package [18,19].
Results and discussion
We begin by identifying the subset of genes whose tran-
script levels change in the presence of the drug letrozole.
Using linear modeling we find that 1044 genes are differ-
entially expressed following 90 days of letrozole treatment
in these tumors. This gene set is comprised of 575 upregu-
lated genes and 469 downregulated genes. Biological pro-
cess annotation through the Gene Ontology shows the
upregulated genes are enriched for cell migration (p =
2.2E-7), positive regulation of gene transcription (p =
1.3E-6), polysaccharide binding (p = 1.0E-6), cell morpho-
genesis involved in differentiation (p = 2.9E-5), ovulation
cycle (p = 1.8E-3) and blood coagulation (p = 2.4E-3). The
downregulated genes are enriched for mitosis (p = 5.9E-
28), micro-tubule cytoskeleton organization (p = 1.2E-15),
DNA repair (p = 1.9E-7), protein targeting to the mito-
chondria (p = 4.2E-5), nucleotide biosynthesis process (p =
9.4E-5) and nucleosome assembly (p = 1.4E-4). These bio-
logical processes are consistent with the broad roles estro-
gen plays in the regulation of gene transcription and
within cell signaling pathways. It is also indicative of the
complexity of estrogen sensitive gene networks. We can
study these networks by modeling gene-gene relationships
over time as the system is perturbed by letrozole. By focus-
ing on the genes that are differentially expressed in
the presence of letrozole we can capture dynamic
relationships.
First, we catalog gene coexpression relationships among
the set of differentially expressed genes at each of the
three time points (i.e. prior to letrozole treatment (pre-
treatment), following 10-14 days (mid-treatment) or fol-
lowing 90 days (post-treatment) of letrozole treatment).
Because we know relationships between genes are com-
plex, we cannot assume the correlation relationships
between gene pairs will be linear. Therefore, we use the
nonparametric Spearman’s rank correlation to determine
coexpression. In addition to capturing nonlinear relation-
ships, this method also avoids some of the bias introduced
by experimental design and data preprocessing methods
that have been shown to affect Pearson’s correlation coef-
ficient [20]. We couple the rank correlation with the 1st-
order partial correlation to remove the effects of common
regulators and to ensure we are only including direct
gene-gene relationships [17].
Second, we use these relationships to assemble three
coexpression networks, one for each time point. The
nodes of the networks represent genes and the links indi-
cate direct correlations between the expression levels of
the pairs of genes they connect. We calculate coexpression
between all pairs of the 1044 differentially expressed genes
which means each network has 1044 nodes and can have
up to 544,446 links. However, only those coexpression
relationships that reach statistical significance are included
as links within a given network. This results in three net-
works that have the same set of nodes but varying num-
bers of links.
These networks map all detectable coexpression rela-
tionships occurring at each of three sequential time
points over the course of letrozole treatment enabling us
to track how the network is rewired as it adapts to the
presence of the drug. Furthermore, we can use structural
properties of the network to prioritize genes for further
analysis that are likely to play functionally relevant roles
in maintaining network integrity and controlling infor-
mation flow throughout the system.
The pre-treatment, mid-treatment, and post-treatment
networks have 2262, 2462, 2858 links, respectively. In
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each network the distribution of links among the 1044
nodes is not uniform but instead exhibits a heavy-tail,
an indication that the networks have highly connected
nodes, or hubs (Figure 1). The degree distributions of
the pre-treatment and mid-treatment networks are not
signficantly different by the Kolmogorov-Smirnov test
(p = 0.1356). The degree distribution of the post-
treatment network does vary signficantly from the mid-
treatment network (p = 0.0023). The number of genes
with low degree decreases while the average degree
increases showing the general trend that more genes
tend to have more links in a time-dependent manner in
the presence of letrozole (Figure 1).
To determine how the differences in the number of
links and connectivities of the networks impact network
topology we measure the mean shortest path lengths
(i.e. the average shortest distance between all pairs of
nodes) and the global clustering coefficients (i.e. the
probability that common neighbors of a given node are
themselves neighbors).
The mean shortest path length is an estimate of net-
work navigability [21]. We calculate the mean shortest
path length within the largest connected component of
each network. The size of the largest connected compo-
nent increases and the mean path length decreases in the
presence of letrozole (Table 1). However, the distances
between the nodes that are part of the largest connected
component are separated on average by approximately
five links, regardless of letrozole treatment status. There
are statistically significant differences in the distributions
of the shortest path lengths between the pre-treatment
and mid-treatment networks (p <.0001) and between the
mid-treatment and post-treatment networks (p <.0001).
This suggests that the increase in links is not providing
alternate routes that shorten the distances between nodes
globally but that the path lengths between specific nodes
are changing in the presence of letrozole.
Each network has a characteristic global clustering
coefficient that estimates the probability that adjacent
nodes of a given node are connected by a link [21,22].
Biological networks have relatively high clustering coeffi-
cients, for example, the neural network of Caenorhabdi-
tis elegans is close to 30% [23]. In our networks, the
global clustering coefficients are low, on the order of 9-
10% regardless of letrozole treatment status (Table 1).
This indicates that pairs of nodes are gaining or losing
links independently as opposed to groups of nodes (i.e.
subgraphs) becoming more connected. Even with an
increase in the number of links the network is not
becoming more cohesive. This suggests that genes are
being independently regulated as they react to the pre-
sence of letrozole and furthermore, that the relation-
ships of individual genes are the distinguishing
characteristics of these networks.
We use bottleneck nodes to survey independent regu-
lation because it has been shown that bottleneck nodes
are regulated in a condition-dependent manner in biolo-
gical networks [24]. We define bottleneck nodes as
nodes that are statistical outliers based on their
betweenness centrality score (Figure 2). The between-
ness centrality score counts the number of shortest
paths that cross a given node. The score is an indication
of how embedded (i.e. central) a node is within the
network.
We also take the hubs of the networks into considera-
tion (Figure 1). As highly connected nodes hubs play an
integral role in maintaining network integrity and in
mass information transfer. We define hubs as nodes
that are statistical outliers in terms of their degree cen-
trality (i.e. number of links).
Figure 1 Degree distributions. Changes in the degree distributions of breast tumor coexpression networks during the course of neoadjuvant
treatment with letrozole. Coexpression networks are built from gene expression data measured at diagnosis (Pre-treatment), following 10-14
days of letrozole treatment (Mid-treatment), and following 90 days of letrozole treatment (Post-treatment). Each network contains 1044 nodes
representing the set of genes differentially expressed following 90 days of letrozole treatment. The number of links vary over the course of
letrozole treatment with 2262, 2242, 2858 links in the pre-treatment, mid-treatment and post-treatment graphs, respectively.
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In protein interaction networks hubs and bottlenecks
have both been associated with functional essentiality
[24-26]. Here we are also interested in their ability to
influence the propagation of signals across a network.
Because hubs have many neighbors, signals that reach
them can be quickly propagated to a large number of
nearby nodes. Bottlenecks may or may not have many
neighbors but they are positioned to create efficient
paths of information-flow throughout an entire network.
In addition, we make the distinction between hub bot-
tlenecks (i.e. high degree and betweenness centralities),
hub nonbottlenecks (i.e. high degree) and nonhub bot-
tlenecks (i.e. high betweenness) (Figure 2).
The majority of hubs and bottlenecks only hold these
prominent positions at one of the three time points
(Figure 3). Accordingly, key genes that are maintaining
network integrity and modulating information-flow
change over time in the presence of the drug.
Of the 1044 differentially expressed genes, 852 or
approximately 82%, are categorized as nonhub nonbottle-
necks at all three time points (Figure 3). The remaining
18% of differentially expressed genes are holding promi-
nent positions in at least one of the three networks. In
most cases, a node categorized as a hub, a bottleneck, or
both becomes a nonhub nonbottleneck gene at the next
time point (Figure 4). In addition, most of the genes that
become hubs, bottlenecks, or both were nonhub nonbot-
tlenecks at the previous time point. This emphasizes that
the relationships of individual genes are dynamically
changing allowing nodes to cycle through positions of
influence. As the network reacts to letrozole perturbation
there is independent regulation of key genes in a time
dependent manner.
Only one gene, ZFHX4, is classified into the same
centrality category, a hub bottleneck, in all three net-
works. The ZFHX4 gene encodes a zinc-finger tran-
scription factor that is upregulated by letrozole.
According to the Human Protein Atlas there is consis-
tent positive staining for ZFHX4 protein in the nucleus
of breast tumor tissue samples and in at least two cell-
lines derived from breast cancers, MCF-7, an ER+ line,
and SK-BR-3, an ER− line [27,28]. The function of
ZFHX4 is unknown but it has been predicted to partici-
pate in protein-protein interactions with androgen
receptor (AR) and peroxisome proliferator-activated
receptor gamma (PPARG) in beef cattle where it is asso-
ciated with the regulation of puberty [29]. Additionally,
ZFHX4 has been associated with neuronal and muscle
differentiation in mice and interferon beta therapy
response in MS patients [30,31]. As a stable hub
Table 1 Topological properties
Number of Nodes Number of Links Largest Connected Component Mean Path Length Global Clustering Coefficient
Pre-treatment 1044 2262 942 5.16 0.090
Mid-treatment 1044 2462 957 5.12 0.089
Post-treatment 1044 2858 982 4.79 0.103
Characteristics of coexpression networks over the course of treatment with letrozole. Coexpression networks are built from gene expression data measured at
diagnosis (Pre-treatment), following 10-14 days of letrozole treatment (Mid-treatment), and following 90 days of letrozole treatment (Post-treatment). The largest
connected component is the number of nodes within the largest subgraph. Mean path length is a measure of the average distance between all pairs of nodes
within the largest connected component of the network. The global clustering coefficient is the probability that neighboring nodes of a given node are
connected.
Figure 2 Centrality distributions. Genes are categorized based on their degree and betweenness centrality scores. Lines indicate the statistical
outlier thresholds for the degree (vertical line) and betweenness centralities (horizontal line). These thresholds are used to categorize genes into
hub-bottlenecks (high degree and high betweenness centralities), hub-nonbottlenecks (high degree), nonhub-nonbottlenecks, and nonhub-
bottlenecks (high betweenness centrality).
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bottleneck across our networks ZFHX4 likely plays a
critical role in breast cancer as well.
There are five genes, BMP2, CYB5R3, DAB2, FAT4, and
GTPBP4, that are consistently categorized as bottlenecks
(either hub bottlenecks or nonhub bottlenecks). Briefly,
BMP2 is a member of the TGFb superfamily and is upre-
gulated by letrozole. It induces bone formation and is
involved in osteoblast differentation and in conjunction
with BMP7 it may prevent breast cancer metastases to the
bone [32]. The signaling relationships between the ER and
BMP2 pathways is well established [33]. Estrogen inihibits
the expression of BMP2 through estrogen receptor signal-
ing, a process that can be reversed with tamoxifen treat-
ment. CYB5R3 has the largest gain in number of links
Figure 3 Common central genes. Venn diagrams illustrating the number of genes common to each centrality category between time points.
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following 90 days of letrozole treatment and it is upregu-
lated by the drug. This gene has known functions in fatty
acid metabolism, cholesterol biosynthesis and drug meta-
bolism [34]. DAB2 functions as a mitogen responsive
phosphoprotein, it is a putative tumor suppressor and it is
upregulated by letrozole. It has been shown in breast can-
cer that the loss of DAB2 enables the epithelial-to-
mesenchymal transition induced by TGFb signaling [35].
Notably, BMP2 and DAB2 are both used as stem cell mar-
kers. FAT4 encodes a tumor suppressor that is lost in a
subset of breast cancer cell-lines and primary breast
tumors [36]. FAT4 is upregulated by letrozole. GTPBP4
encodes a GTPase that is downregulated by letrozole.
RNAi screening has revealed an interaction between
GTPBP4 and p53 and the authors confirm that elevated
levels of GTPBP4 in p53 WT breast tumors are inversely
correlated with survival [37]. As enduring bottlenecks,
these genes have links that maintain paths of information-
flow throughout the networks.
One gene, CAV1, is consistently categorized as a hub
(either a hub bottleneck or a hub nonbottleneck). CAV1
encodes a scaffolding protein that is a tumor suppressor
candidate and it is upregulated by letrozole. CAV1 has
been shown to target ERa to the cell membrane [38].
Extensive studies of CAV-1 in normal and tumor tissue
have revealed its many roles in cell morphology, adhesion,
remodeling of the tumor microenvironment, tumor cell
invasion and metastic potential [39]. As an enduring hub,
CAV1 plays a central role in maintaining coexpression
network integrity.
Genes that have transiently high centrality scores are
likely playing condition-dependent functional roles.
There are 146 genes that are categorized as hubs, bottle-
necks, or both in only one of the three networks. Briefly,
the pre-treatment network has 49 of these genes includ-
ing ID3, a gene that is upregulated by letrozole and
involved in estrogen stimulated vascularization, and
IGF1R a gene that is downregulated by letrozole and
whose downregulation is associated with tamoxifen
resistance in cell-lines and xenograft models [40,41].
The mid-treatment network has 50 of these genes
including TACC1, a gene that is upregulated by letro-
zole and whose overexpression is associated with tamox-
ifen resistance, and RAD51 a gene that is downregulated
by letrozole with a functional role in homologous
recombination and known interactions with BRCA1 and
BRCA2 [34,42,43]. The post-treatment network accounts
for the remaining 47 genes in this group including PGR
which is downregulated by letrozole and has a well-
established role in hormone responsive cancers includ-
ing breast cancer and TCF4 which induces osteoblast
proliferation and differentiation and encodes a protein
that physically interacts with ERa through the Wnt sig-
naling pathway [44].
In addition, there are 39 genes that are hubs or bottle-
necks at two of the three time points. A few of these are
known estrogen responsive genes, for example, FOXO1
and KIAA0101. A complete list of differentially expressed
genes with their centrality statuses are presented in Addi-
tional file 1.
Figure 4 Centrality classifications by treatment status. Diagram illustrating the temporal positioning of genes within the coexpression network.
Each row indicates a centrality category and each column indicates a time point. Arrows show how genes move between centrality categories over
the course of letrozole treatment. Arrow thickness is proportional to the log of the number of genes being represented by a given arrow.
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In order for nodes to have temporal influence they must
either gain or lose enough links to change their own sta-
tus, gain or lose one or more critical neighbors, or sur-
rounding nodes must gain or lose enough links to change
the status of a given node. Early response to letrozole
treatment leads to the formation of additional relation-
ships for the majority of genes (484/1044) (Figure 5).
Although, the proportion of genes that have an initial loss
of links is nearly as large (415/1044). The transition from
early response to late response results in 540 and 358
genes gaining or losing links, respectively. Some nodes do
have a consistent degree throughout the course of
letrozole treatment however, stable degree is not a proxy
for stable gene-gene relationships.
We counted the number of links that are conserved
between both transitions from the pre-treatment to mid-
treatment networks and from the mid-treatment to post-
treatment networks. We find that approximately 20% of
links are conserved between each of the time transitions
meaning that 80% of gene-gene relationships are not stable
throughout the course of letrozole treatment. This is con-
sistent with a study of synthetic lethality in yeast which
demonstrated that greater than 70% of the links represent-
ing epistatic relationships in a gene network following
Figure 5 Patterns of degree change. Nodes may have an increase, decrease, or no change in degree as they adapt to the presence of
letrozole. These plots illustrate the changes in degree of each node and the distribution of nodes across the nine possible patterns of change.
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treatment with a DNA damaging agent are not present
before-hand [45]. We show that coexpression networks
are equally dynamic, continually rewiring in a condition
dependent manner.
Partial correlation yields many false-negatives (i.e. not
identifying relationships that are actually present in the
data); however, the number of false positives (i.e. identify-
ing relationships that are statistical artifacts) is neglible
[17]. We are not concerned by the false negative links
because our intention is not to reconstruct the entire gene
regulatory network but instead to find similarities and dif-
ferences between the condition specific networks. By using
partial correlation to estimate coexpression we are confi-
dent that the links we identify are real and that the neigh-
bors of each gene in each network are the optimal set of
genes to explain the variation of a given gene within this
data set.
The essentiality of hubs and bottlenecks has been
debated in the literature with experimental evidence in
support of both sides [25,26,46,47]. Here, we show that
hubs and bottlenecks are transient in a time-dependent
and condition-specific manner. Our results suggest that
the underlying context determines the importance of each
of these nodes. It is entirely feasible that nodes categorized
as hubs and bottlenecks are only essential some of the
time.
Due to the nature of coexpression all relationships are
reciprocal so we cannot infer functional directions along
the links. However, through literature validation we have
shown that coexpression networks can provide a means of
prioritizing genes that may play an especially important
role as gene networks adapt to letrozole perturbation. As
additional data measuring gene expression before and
after letrozole treatment in vivo is collected and made
available we will be able to validate this method and these
results. Until then, our results can be used to generate tes-
table hypotheses about letrozole’s action or more generally
about ER+ breast cancer (e.g. the role of ZFHX4).
Conclusions
Genomic data has the potential to reveal dynamic rela-
tionships between genes if analyzed in a way that
respects the global set of interactions that underlie bio-
logical function. Network models can complement the
more traditional differential expression analysis methods
by revealing genes that have the potential to propagate
information throughout entire gene networks changing
gene-gene relationships along the way. In a letrozole
perturbed breast tumor coexpression network we have
identified key genes for modulating information flow at
each of three treatment time points. Many of these
genes are specific to either the pre- treatment, mid-
treatment or post-treatment conditions which empha-
sizes the context-dependent assembly and dynamic
nature of gene networks. By understanding how net-
works are rewired by letrozole treatment and which
genes seem to mediate these effects we can begin to
explore mechanisms of letrozole response or resistance.
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